The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).
 
Jonathan S. Zager
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Honoraria - Amgen; Castle Biosciences; Merck; Pfizer; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - Castle Biosciences; Delcath Systems; Philogen; Sanofi/Regeneron
Speakers' Bureau - Pfizer; Sun Pharma
Research Funding - Castle Biosciences (Inst); Delcath Systems (Inst); NeraCare GmbH (Inst); Philogen (Inst); Provectus (Inst)
Patents, Royalties, Other Intellectual Property - US Patent 10,583,246
Expert Testimony - Bubalo Law; McGowan, Hood, Felder & Phillips, LLC
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Merck
 
Marlana M. Orloff
Consulting or Advisory Role - IDEAYA Biosciences; Immunocore; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Linnaeus Therapeutics (Inst); Plexxikon (Inst)
 
Pier Francesco Ferrucci
Expert Testimony - Delcath Systems
 
Evan Scott Glazer
Research Funding - Delcath Systems (Inst)
Patents, Royalties, Other Intellectual Property - Anviron stock options
Travel, Accommodations, Expenses - Medtronic
 
Aslam Ejaz
No Relationships to Disclose
 
Erika Richtig
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Merck; Merck Sharp Dohme; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pierre Fabre (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi
 
Sebastian Ochsenreither
Honoraria - AstraZeneca; BMS; Ipsen; Merck Serono; MSD
Consulting or Advisory Role - Bayer; BMS; Janssen-Cilag; Merck Serono; MSD
Research Funding - BMS
Patents, Royalties, Other Intellectual Property - Cyclin A1 as T-cell target
Travel, Accommodations, Expenses - BMS; Merck Serono
 
Michael C. Lowe
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); Regeneron (Inst); Vaccinex (Inst)
 
Sunil A. Reddy
No Relationships to Disclose
 
Georgia Beasley
Honoraria - National Comprehensive Cancer Network
Consulting or Advisory Role - Cardinal Health; Regeneron
Research Funding - Checkmate Pharmaceuticals (Inst); Delcath Systems (Inst); Istari Oncology (Inst); Oncosec (Inst); Replimune (Inst)
 
Anja Gesierich
No Relationships to Disclose
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Ana Maria Arance
Consulting or Advisory Role - BMS; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - BMS; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Research Funding - BMS (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - BMS; MSD; Novartis; Pierre Fabre
 
Stephen William Fenwick
Consulting or Advisory Role - Medac
 
Matthew Wheater
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; MSD; Pfizer; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Healthcare at Home; Novartis
Research Funding - AVEO (Inst); GlaxoSmithKline/Novartis (Inst); GlaxoSmithKline/Novartis (Inst); MSD (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; MSD; Novartis
 
Christian Ottensmeier
No Relationships to Disclose